key: cord-0802153-9tqjyjn4
authors: Guilpain, Philippe; Noël, Danièle; Avouac, Jérôme
title: Editorial: Key Players in Systemic Sclerosis: The Immune System and Beyond
date: 2021-09-30
journal: Front Immunol
DOI: 10.3389/fimmu.2021.770419
sha: c2a835ff1b40e77407bdf7fedf741b260d49260e
doc_id: 802153
cord_uid: 9tqjyjn4

nan

advances in our understanding of the crucial actors and mechanisms that underlie this disease are essential for improving therapy (hopefully, through the development of innovative therapeutic approaches) and patient outcomes.

In fact, a myriad of questions regarding SSc pathogenesis still remain unresolved. By exploring the most recent advances and discoveries in this field, this Research Topic aimed to transition our understanding of SSc pathogenesis from its old conception (based on the three main mechanisms, i.e. autoimmunity, fibrogenesis and vascular involvement) to a modern view.

When we proposed this topic to Frontiers in Immunology (https://www.frontiersin.org/research-topics/7231/key-players-insystemic-sclerosis-the-immune-system-and-beyond#overview), the most recent advances in SSc had included the following key points (2): (i) fibroblast activation and endothelial impairment are likely dependent on environmental, genetic and epigenetic factors, with a specific contribution of endogenous and/or exogenous oxidative stress; (ii) a link was recently established between cancer and some specific forms of SSc [with particular autoantibodies (i.e. anti-RNA polymerase III and related Abs)], illustrating that the immune response could be directed against malignant targets; (iii) metabolic pathways (such as those implicating PPAR-g) were also likely important for SSc development and could represent innovative therapeutic targets; (iv) while autologous hematopoietic stem cell transplantation following intensive immunosuppressant therapy had convinced more and more SSc specialists of its interest, progenitor cell-based therapies [such those using mesenchymal stromal cells (MSC)] were under development with great promises; (v) additionally, several pharmacological approaches were also under development to counteract fibrosis and vascular impairment in SSc.

The present Research Topic is entitled "Key players in Systemic Sclerosis -The immune system and beyond…", since key players in SSc are not limited to the immune system. This is one of the most original specificities of the disease. So, in the present Research Topic, we proposed 20 articles (including 10 review articles and 10 original articles) in the field of SSc, focusing on various cellular, molecular and environmental actors involved in SSc, in relationship with the immune system, and on innovative therapies for SSc. So, you can read in the present book, two original articles on Abs Three years and one pandemic later, the content of this book remains fully relevant and continues to shed light on new ways of understanding and treating SSc. We would now like to highlight some of the data and concepts described in this book, and discuss them in light of other recent studies.

We encourage the reading of the review article on the innate immune system (Laurent et al.) . While macrophages and type I interferon have been considered for many years as key players in SSc, several other components of the innate immune system (such as pathogen-recognition receptors, platelet-derived dangerassociated molecular patterns, innate lymphoid cells, and plasmacytoid dendritic cells) exhibit now an emerging role. Research on the subject is ongoing and promising. A recent study (3) demonstrates the role of innate lymphoid cells-2 (ILC2) both in human and murine SSc, and more precisely the interplay between these cells and cytokines (namely, TGFb and IL10) in the development of fibrosis. Interestingly, TGFb could induce the switch of ILC2 from an 'inflammatory' phenotype (KLRG1 high ) to a 'natural' phenotype (KLRG1 low ), which exhibits a more potent capacity for fibrogenesis. Even more interesting, pharmacological TGFb blockade with the anti-fibrotic agent pirfenidone did not significantly reduce the fibrotic process, while a combined treatment with pirfenidone and IL10 did. This therapeutic response was associated with a reduced number of skin infiltrating ILC2 and an enhanced expression of KLRG1. These findings illustrate the complexity of the disease as well as the variety of interactions between key players, both at the molecular and cellular levels, and suggest that combined therapies may be the future.

T-cell costimulation pathways (such as CD28/CTLA-4, ICOS-B7RP1, CD70-CD27, CD40-CD154, or OX40-OX40L) may be key players in the pathogenesis of SSc, as suggested by several experimental findings (Boleto et al.) . Notably, the blockade of T-cell costimulation with abatacept (CTLA-4-Ig) improved the various manifestations of SSc in pre-clinical animal models (4, 5) and these promising results were corroborated by some preliminary clinical reports (6, 7) . Interestingly, abatacept prevented the development of inflammation-driven fibrosis, but demonstrated no efficacy in the treatment of late and noninflammatory dermal fibrosis (4). Unfortunately, a recent trial (ASSET trial, NCT02161406) did not confirm the promises ofabatacept for patients with early diffuse SSc, considering the modified Rodnan skin thickness score (mRSS) at 12 months as primary endpoint (8) . Nevertheless, according to this trial, abatacept remains promising when considering some secondary endpoints, i.e. the "Health Assessment Questionnaire disability index" (HAQ) and the composite score called "American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis (ACR CRISS)". These two scores reflect respectively the disability induced by SSc and the probability of improvement in response to treatment in patients with early diffuse cutaneous SSc. Undoubtedly, all these findings illustrate also the complexity and heterogeneity of the disease, as well as the difficulty to monitor SSc and to determine the different components of the disease for a given patient (inflammatory versus dry fibrosis, for example). It also reminds us that encouraging results obtained in animals do not presume a success in humans. So, these -almost-negative results with abatacept suggest that CD28 pathway inhibition alone is insufficient to significantly impact skin disease in patients with early diffuse SSc, and suggest the co-targeting of CD28 with another costimulatory molecule to gain efficacy. For instance, the development of a dual CD28/ICOS antagonist (ALPN-101) may be of interest, since the blockade of both CD28 and ICOS in an acute graft versus host mouse model led to improved survival in ALPN-101-treated mice compared to mice receiving a CD28-CD80/CD86 pathway antagonist (belatacept; CTLA-4-Ig) only (9) .

This book also includes a short collection of articles on cell- , and we would like to shortly discuss the progress of knowledge in this field, more precisely on MSC-based therapies. The questions concerning the source and origin of MSC are still under debate, in particular the use of an autologous versus allogeneic approach (23). Concerning MSC and SSc, 12 studies are registered today on the site "ClinicalTrials.gov", with several distinct methodological approaches. So, we can expect to get answers to many questions in the months and years to come. Another perspective in the field of MSC is represented by their extracellular vesicles (EVs), that function as mediators of intercellular communication and natural transporters of bioactive molecules (proteins, RNA, DNA) to their microenvironment or systemically. Actually, MSC-derived EVs exhibit the main functions of MSC, and thus could constitute an attractive alternative to MSC, i.e. not suffering from the potential issues associated with expanded cells. In addition, EVs possess the advantage to be safer (anuclear) and could be stored at room temperature as lyophilized product (10) . Recently, our group demonstrated the beneficial effects of EVs obtained from adipose tissue-derived MSC (ASC), both in vivo in the HOCl-induced SSc model (11) and in vitro in a TGFb1-induced model of human myofibroblasts, mimicking the characteristics of fibroblasts isolated from SSc patients (12) . We also demonstrated that miR-29a-3p (contained in the EVs) plays a pivotal role for the therapeutic effects of ASC, probably by targeting fibrotic, remodeling, apoptotic, and epigenetic processes (11) . These findings make even more sense when considering the different key players and mechanisms described in this book. Finally, in parallel with the development of pharmacological molecules, research on cell therapies is also progressing, with interesting therapeutic prospects using the cells or their derived vesicles.

SSc is definitely a complex disease with many key players, which for a long time escaped our understanding and, which we know better, day by day. The challenge of SSc remains still very important, both pathophysiologically and therapeutically. We hope you enjoy reading this book. We hope that it will open up new perspectives for all SSc specialists, and also for all others in their own fields of research.

Systemic Sclerosis

Systemic Sclerosis: Recent Insights

Tgfb Promotes Low IL10-Producing ILC2 With Profibrotic Ability Involved in Skin Fibrosis in Systemic Sclerosis

Treatment With Abatacept Prevents Experimental Dermal Fibrosis and Induces Regression of Established Inflammation-Driven Fibrosis

T-Cell Costimulation Blockade Is Effective in Experimental Digestive and Lung Tissue Fibrosis

Outcomes of Patients With Systemic Sclerosis-Associated Polyarthritis and Myopathy Treated With Tocilizumab or Abatacept: A EUSTAR Observational Study

Abatacept Induces Clinical Improvement in Patients With Severe Systemic Sclerosis

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial

ICOSL+ Plasmacytoid Dendritic Cells as Inducer of Graft-Versus-Host Disease, Responsive to a Dual ICOS/CD28 Antagonist

Mesenchymal Stem Cell-Derived Extracellular Vesicles: Opportunities and Challenges for Clinical Translation

Editorial: Key Players in Systemic Sclerosis Frontiers in Immunology | www

Mesenchymal Stromal Cells-Derived Extracellular Vesicles Alleviate Systemic Sclerosis Via miR-29a-3p

Extracellular Vesicles Are More Potent Than Adipose Mesenchymal Stromal Cells to Exert an Anti-Fibrotic Effect in an In Vitro Model of Systemic Sclerosis

All three authors contributed to the editing of the Research Topic, writing and reviewing of the present Editorial article. All authors contributed to the article and approved the submitted version.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.